-
Something wrong with this record ?
Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line
N. Cernei, O. Zitka, S. Skalickova, J. Gumulec, M. Sztalmachova, MA. Rodrigo, J. Sochor, M. Masarik, V. Adam, J. Hubalek, L. Trnkova, J. Kruseova, T. Eckschlager, R. Kizek,
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2006 to 1 year ago
ProQuest Central
from 2012-01-01
Health & Medicine (ProQuest)
from 2012-01-01
PubMed
23588590
DOI
10.3892/or.2013.2389
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Metallothionein metabolism MeSH
- Biomarkers, Tumor pharmacology physiology MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms MeSH
- Sarcosine pharmacology physiology MeSH
- Free Radical Scavengers metabolism MeSH
- Cell Survival MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040814
- 003
- CZ-PrNML
- 005
- 20140114110250.0
- 007
- ta
- 008
- 140107s2013 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3892/or.2013.2389 $2 doi
- 035 __
- $a (PubMed)23588590
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Cernei, Natalia
- 245 10
- $a Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line / $c N. Cernei, O. Zitka, S. Skalickova, J. Gumulec, M. Sztalmachova, MA. Rodrigo, J. Sochor, M. Masarik, V. Adam, J. Hubalek, L. Trnkova, J. Kruseova, T. Eckschlager, R. Kizek,
- 520 9_
- $a Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 µM) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 µM) to 106 µM with the highest applied concentration of sarcosine (1,500 µM). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at p<0.001) and between DMPD and ABST (r=-0.64 at p<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at p<0.001) was observed.
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a scavengery volných radikálů $x metabolismus $7 D016166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metalothionein $x metabolismus $7 D008668
- 650 _2
- $a nádory prostaty $7 D011471
- 650 _2
- $a sarkosin $x farmakologie $x fyziologie $7 D012521
- 650 _2
- $a nádorové biomarkery $x farmakologie $x fyziologie $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zitka, Ondrej $u -
- 700 1_
- $a Skalickova, Sylvie $u -
- 700 1_
- $a Gumulec, Jaromir $u -
- 700 1_
- $a Sztalmachova, Marketa $u -
- 700 1_
- $a Rodrigo, Miguel Angel Merlos $u -
- 700 1_
- $a Sochor, Jiri $u -
- 700 1_
- $a Masarik, Michal $u -
- 700 1_
- $a Adam, Vojtěch $u - $7 xx0064599
- 700 1_
- $a Hubalek, Jaromir $u -
- 700 1_
- $a Trnkova, Libuse $u -
- 700 1_
- $a Kruseova, Jarmila $u -
- 700 1_
- $a Eckschlager, Tomas $u -
- 700 1_
- $a Kizek, Rene $u -
- 773 0_
- $w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 29, č. 6 (2013), s. 2459-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23588590 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140114110955 $b ABA008
- 999 __
- $a ok $b bmc $g 1005210 $s 839326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 29 $c 6 $d 2459-66 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
- LZP __
- $a Pubmed-20140107